The American Journal of Medical Sciences and Pharmaceutical Research
15
https://www.theamericanjournals.com/index.php/tajmspr
TYPE
Original Research
PAGE NO.
15-21
10.37547/tajmspr/Volume07Issue07-03
OPEN ACCESS
SUBMITED
07 June 2025
ACCEPTED
24 June 2025
PUBLISHED
26
July 2025
VOLUME
Vol.07 Issue 07 2025
CITATION
Efim Iuresku. (2025). Generative AI In Life Sciences: Unlocking
Operational Value Across the Product Lifecycle. The American Journal
of Medical Sciences and Pharmaceutical Research, 7(07), 15
–
21.
https://doi.org/10.37547/tajmspr/Volume07Issue07-03
COPYRIGHT
© 2025 Original content from this work may be used under the terms
of the creative commons attributes 4.0 License.
Generative AI In Life
Sciences: Unlocking
Operational Value Across
the Product Lifecycle
Efim Iuresku
Engagement Manager, Strategic Consulting Firm
New York City, USA
Abstract:
The development and commercialization of
pharmaceutical and MedTech products represent one of
the most complex and resource-intensive endeavors in
the modern economy. The process involves long
timelines, high attrition rates, and the integration of vast
volumes of structured and unstructured data.
Generative artificial intelligence (GenAI) has emerged as
a transformative tool capable of enhancing efficiency,
accelerating scientific discovery, and streamlining
operations across the life sciences value chain - from
early research to clinical development, manufacturing,
medical affairs, and commercialization.
A
synthesis
of
current
literature,
real-world
implementations, and industry benchmarks was
conducted to evaluate high-impact application areas of
GenAI in life sciences. Documented use cases from
biopharmaceutical and MedTech organizations illustrate
the deployment of GenAI in target identification, de
novo molecule generation, trial protocol design, medical
writing automation, manufacturing deviation analysis,
medical engagement support, and omnichannel content
generation.
Estimates indicate that GenAI could unlock between $60
billion and $110 billion in annual value across the
pharmaceutical industry. The greatest economic
potential lies in commercial functions, followed by
research and clinical development. Early adopters -
including Pfizer, Novartis, AstraZeneca, and Novo
Nordisk - have reported productivity improvements
ranging from 20% to 60% in pilot programs focused on
regulatory documentation, manufacturing quality, and
HCP engagement.
The American Journal of Medical Sciences and Pharmaceutical Research
16
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
Despite these benefits, large-scale adoption remains
constrained by several challenges. Key barriers include
hallucination risks in language models, regulatory
ambiguity, limitations in technical infrastructure and
data quality, and resistance to organizational change.
Addressing these constraints will be critical to ensuring
the safe, compliant, and impactful integration of GenAI
technologies into life sciences workflows.
Keywords:
Generative AI; Life sciences; Pharmaceutical
operations; Pharma digital transformation
1.
Introduction
The
development
and
commercialization
of
pharmaceutical and MedTech products is among the
most complex and data-intensive undertakings in the
modern economy. Spanning over a decade, involving
billions of dollars in investment, and requiring
navigation through rigorous scientific, regulatory,
operational, and commercial hurdles, the process is
inherently high-risk and high-cost. Companies must
synthesize vast volumes of structured and unstructured
data - from genomic sequences and digital pathology
slides to clinical trial reports, supply chain metrics, and
real-world patient data - across siloed systems and
globally distributed teams.
In this environment, Generative AI (GenAI) has emerged
as a transformative technology with the potential to
fundamentally reshape how organizations discover,
develop, and deliver therapies. Unlike traditional
analytical AI, which has already shown impact through
classification and prediction tasks, GenAI introduces
novel capabilities such as large-scale content
generation, synthesis of scientific literature, intelligent
summarization, and deep pattern recognition across
heterogeneous datasets. These capabilities are
particularly valuable in life sciences, where the ability to
navigate scientific complexity, accelerate decision-
making, and automate labor-intensive knowledge work
is a strategic differentiator [1].
Early adopters of GenAI in pharma have focused on
target identification and molecular design, but the
opportunity extends much further. Real-world pilots
now demonstrate impact in clinical development,
regulatory submission preparation, manufacturing
deviation management, supply chain optimization,
medical content generation, and even commercial
personalization at scale [1][2].
However, capturing this value is far from plug-and-play.
The successful application of GenAI depends not only on
the quality of foundation models, but also on the
readiness of underlying data architectures, the ability to
embed new workflows into operating models, and the
strength of governance frameworks addressing
regulatory, ethical, and security risks [9].
This article explores the most promising applications of
GenAI across the life sciences value chain. Drawing on
proprietary insights, industry case examples, and
emerging benchmarks, we provide a high-level
framework to assess where GenAI can unlock
meaningful value - from R&D to market - and how
companies can approach adoption responsibly and
effectively [2][3].
2.
Materials and Methods
This article synthesizes insights from recent external
publications, scientific literature, and publicly disclosed
examples of Generative AI (GenAI) adoption across the
life sciences industry. The analysis is structured around
five stages of the pharmaceutical and MedTech value
chain:
research
and
early
discovery,
clinical
development, manufacturing and supply chain, medical
affairs, and commercialization.
Use cases were selected based on clear evidence of real-
world implementation, business relevance, and
availability of verifiable impact metrics. Preference was
given to examples disclosed by leading organizations in
the industry, including pharmaceutical, biotechnology,
and medical device companies, through corporate
websites, investor briefings, and regulatory filings.
To ensure a comprehensive and balanced perspective,
findings were triangulated across academic journals,
official regulatory reports, and strategic insights
published by consulting firms and technology providers.
The goal was to capture both the potential and practical
limitations of GenAI adoption in highly regulated, data-
intensive environments.
3.
Functional Impact of GenAI in Life Sciences
Generative AI (GenAI) is expected to generate between
$60 billion and $110 billion in annual value across the
pharmaceutical industry value chain [1]. The projected
value is not uniformly distributed; instead, it varies by
The American Journal of Medical Sciences and Pharmaceutical Research
17
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
function depending on task structure, data intensity, and existing digital maturity
(see Figure 1)
.
Figure 1. Expected GenAI impact for Life Sciences
The greatest value potential lies in commercial functions
($18-30B), followed by research and early discovery
($15-28B), clinical development ($13-25B), enterprise
functions such as IT, finance, and legal ($8-16B),
operations ($4-7B), and medical affairs ($3-5B) [1][7].
This distribution reflects not only the scale of these
functions but also the breadth of high-frequency, high-
leverage use cases well suited for GenAI technologies.
Importantly, these value estimates are grounded in
tangible early outcomes. For example, in R&D, GenAI
applications have reduced molecule design cycles by
over 50% and improved the probability of clinical trial
success by 10% or more. In operations and
manufacturing, deviation root-cause analysis, predictive
maintenance, and quality reviews have been
streamlined, resulting in up to 40%-time savings. In
commercial and medical domains, productivity gains of
20-80% have been reported in content generation, field
medical support, and customer engagement [1][3][5].
The following sections explore these functional domains
in greater depth, highlighting 3-4 of the most promising
application areas in each, accompanied by real-world
use cases where available.
3.1 Research and Early Discovery
Research and early discovery remain one of the most
active and high-potential areas for GenAI deployment in
life sciences. With an estimated value potential of $15
–
28 billion annually [1], this phase benefits from the
convergence of complex multimodal data (e.g., omics,
literature, structures), computational modeling, and
high failure rates - conditions well suited for GenAI-
driven acceleration and augmentation.
Key Application Areas
1.
Target identification and indication expansion
(understand
disease
mechanisms)
Multi-modal foundation models are used to analyze
disease biology by synthesizing omics data, scientific
literature, and clinical evidence. This enables the
identification of novel therapeutic targets and
indication repurposing opportunities, particularly
for complex or rare conditions [1][5].
2.
In silico compound screening
(prioritize best-fit
molecules)
GenAI enables AI-driven prioritization of large
compound
libraries
by
simulating
target
interactions, predicting binding affinity, and
identifying
toxicity
risks.
This
significantly
accelerates early filtering of viable candidates
before synthesis [1][5].
3.
De novo molecule generation
(design novel
compounds
from
scratch)
Foundation models trained on chemical and
biological data can propose entirely new molecules
optimized for specific targets. These models
integrate chemical logic, 3D structural data, and
pharmacological constraints to accelerate discovery
and reduce wet-lab cycles [3][5].
4.
Self-driving laboratories and design loops
(automate
and
optimize
experimentation)
GenAI is increasingly integrated with robotic
The American Journal of Medical Sciences and Pharmaceutical Research
18
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
platforms to create closed-loop R&D systems.
Models
suggest
next
experiments,
update
hypotheses in real time, and drive faster iteration
through AI-guided synthesis and testing.
Illustrative Use Case
A publicly known example is Insilico Medicine, which
applied GenAI to accelerate both target identification
and molecular design for idiopathic pulmonary fibrosis.
Using its proprietary Chemistry42 platform, the
company progressed a novel compound from target
discovery to IND submission in under 18 months -
demonstrating a substantial reduction in early discovery
timelines [10]
3.2 Clinical Development
Clinical development accounts for a significant portion
of pharmaceutical R&D costs and timelines, often
stretching over 6
–
8 years with high failure rates and
substantial operational complexity. GenAI offers
opportunities to reduce cost, increase trial success
probability,
and
accelerate
timelines
through
automation, insight generation, and dynamic process
optimization. The estimated annual value potential in
this domain is $13
–
25 billion [1].
Key Application Areas
1.
Protocol design and feasibility assessment
(optimize
study
setup)
GenAI models can synthesize historical trial data,
scientific literature, and real-world evidence to
generate or optimize trial protocols. They help
assess
inclusion/exclusion
criteria,
suggest
endpoints,
and
simulate
feasibility
across
geographies and populations [1][7].
2.
Patient recruitment and site selection
(improve
targeting
and
speed
up
enrollment)
By analyzing EMRs, prior recruitment performance,
and demographic data, GenAI can help identify
optimal sites and patient cohorts, reducing
recruitment timelines and improving trial diversity
[1][7].
3.
Medical writing and submission preparation
(automate
regulatory
documents)
Large language models can draft clinical study
reports (CSRs), investigator brochures, and
submission dossiers based on structured trial
outputs and pre-trained regulatory formats. This
reduces time-to-submission and documentation
burden [5][7].
4.
Adverse event detection and monitoring
(enhance
patient
safety
through
signal
analysis)
GenAI can synthesize patient records, trial
monitoring data, and external safety databases to
detect potential adverse event patterns in near real-
time, allowing for earlier interventions and
improved pharmacovigilance [5][7].
Illustrative Use Case
Pfizer has piloted GenAI tools to streamline the drafting
of clinical study reports and investigator brochures.
These tools integrate structured trial data, statistical
outputs, and standard regulatory language formats.
Initial results demonstrated a reduction in preparation
time of up to 40%, along with improved consistency and
reduced burden on regulatory staff [11].
3.3 Manufacturing and Supply Chain
Pharmaceutical and MedTech manufacturing operates
under strict regulatory oversight, high batch complexity,
and long lead times. Supply chains are global, often
fragmented, and vulnerable to disruption. GenAI
provides a unique opportunity to enhance visibility,
accelerate root-cause analysis, reduce downtime, and
optimize inventory - all within validated environments.
Estimated value potential: $4
–
7 billion annually [1].
Key Application Areas
1.
Deviation investigation and root-cause analysis
(accelerate
issue
resolution)
GenAI models trained on historical deviation logs,
batch records, and operator notes can suggest likely
root causes of deviations and propose mitigation
strategies in real time [3][5][8].
2.
Predictive maintenance and asset optimization
(prevent
equipment
failures)
By analyzing IoT sensor data, maintenance logs, and
process
performance,
GenAI
can
forecast
equipment failures and optimize service schedules,
reducing unplanned downtime and improving
throughput [3][5][8].
3.
Batch record review and release automation
(streamline
QA/QC
processes)
LLMs can analyze batch documentation for
The American Journal of Medical Sciences and Pharmaceutical Research
19
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
completeness and anomalies, flag inconsistencies,
and pre-generate QA summaries, significantly
accelerating batch release without compromising
compliance [3][5][8].
4.
Supply chain forecasting and scenario planning
(increase
resilience
and
service
levels)
GenAI supports scenario-based planning by
generating demand forecasts, risk models, and
response strategies based on market signals,
production constraints, and historical disruptions.
Illustrative Use Case
Novartis has implemented GenAI-powered digital twins
across several manufacturing sites to model process
behavior, predict deviations, and support proactive
decision-making. In one pilot, the company combined
process data with GenAI tools to detect quality risks
early and recommend control adjustments - resulting in
a reported 30% reduction in batch deviations and 15%
improvement in release cycle time [12].
3.4 Medical Affairs
Medical affairs plays a critical role in bridging scientific
knowledge with clinical practice and engaging
healthcare professionals (HCPs) with credible, timely,
and personalized information. However, this function is
often constrained by fragmented data, manual content
generation, and inconsistent medical engagement.
GenAI has the potential to significantly enhance
scientific communication, reduce time-to-response, and
scale personalized interactions. Estimated value
potential: $3
–
5 billion annually [1].
Key Application Areas
1.
Medical content generation and summarization
(scale
high-quality
materials
faster)
GenAI can synthesize clinical publications, internal
data, and guidelines to generate or update slide
decks, FAQs, standard response letters, and MSL
materials - freeing up medical staff for high-value
work [3][4].
2.
HCP engagement and question response
(enable
real-time,
personalized
interactions)
Virtual medical copilots powered by GenAI can
support MSLs during field visits or serve as self-
service channels for HCPs, providing on-demand,
evidence-based answers tailored to specialty and
context [3][4].
Illustrative Use Case
AstraZeneca has deployed GenAI-powered tools to
support its medical affairs teams in generating scientific
content and answering complex HCP questions. In pilot
programs, these tools produced field-ready materials
60% faster and enabled real-time support during MSL
engagements. The company also reported increased
consistency in messaging and reduced reliance on
manual literature reviews [13].
3.5 Commercialization
Commercial functions in life sciences are undergoing
rapid transformation as companies shift from broad,
one-size-fits-all strategies to personalized, data-driven
engagement. GenAI is accelerating this shift by enabling
content automation, channel optimization, and micro-
segmentation
at
scale.
Among
all
domains,
commercialization has the highest projected value
capture:
$18
–
30 billion annually
[1].
Key Application Areas
1.
Omnichannel content creation and localization
(automate
tailored
messaging)
GenAI
can
generate
localized,
compliant
promotional materials across channels - email,
digital ads, rep-triggered content - based on clinical
data and HCP preferences [1][3].
2.
Next-best-action recommendation
(optimize rep
engagement
in
real
time)
Models synthesize CRM data, channel behavior,
prescription trends, and prior interactions to
dynamically recommend when, how, and what
message a sales rep should deliver [4].
3.
Segmentation and persona modeling
(refine
targeting
strategy)
By analyzing behavioral and attitudinal data, GenAI
can identify granular HCP personas and match
engagement tactics accordingly - improving reach
and conversion rates [2][4].
4.
Field force enablement
(enhance rep performance
with AI copilots)
Sales reps are increasingly supported by GenAI tools
that summarize patient/HCP profiles, suggest
talking points, and respond to medical queries,
The American Journal of Medical Sciences and Pharmaceutical Research
20
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
allowing for more productive in-person or virtual
visits [3].
Illustrative Use Case
Novo Nordisk has leveraged GenAI to scale omnichannel
personalization across its diabetes portfolio. By
integrating GenAI into its commercial tech stack, the
company automated content creation for emails, rep
tools, and digital ads tailored to specific HCP segments.
The initiative led to a 20% increase in engagement rates
and enabled reps to shift time from admin tasks to high-
value interactions [14].
Discussion: Key Risks and Adoption Barriers
While the promise of GenAI across life sciences is
significant, its broad adoption remains constrained by a
set of critical challenges that organizations must address
to ensure responsible, scalable impact.
1.
Hallucinations and factual reliability
Even state-of-the-art large language models can
generate inaccurate or fabricated content,
particularly when prompted on complex medical or
scientific subjects. Without robust validation
mechanisms, such hallucinations pose risks to
scientific integrity and regulatory compliance [9].
2.
Lack of regulatory guidance
Global regulatory agencies have not yet provided
comprehensive frameworks for the use of GenAI in
clinical, manufacturing, or commercial contexts.
This regulatory uncertainty inhibits deployment in
GxP environments and slows investment in high-
stakes applications.
3.
Insufficient technical and data foundations
Many life sciences organizations lack the necessary
data infrastructure, interoperability, or AI talent to
deploy GenAI at scale. Fragmented systems, limited
labeled datasets, and unstructured documents
make integration costly and error-prone.
4.
Security and patient data privacy risks
The use of GenAI in handling sensitive clinical or
patient data raises significant privacy concerns.
Ensuring HIPAA, GDPR, and other compliance
standards while leveraging foundation models
remains an open technical and governance
challenge [2][8].
5.
Organizational resistance and change management
Many GenAI use cases require rethinking existing
workflows, roles, and incentives. Without strong
leadership and operational enablement, even high-
ROI pilots risk stalling at the proof-of-concept stage
[3][5].
4.
Conclusion
Generative AI represents a paradigm shift in how life
sciences organizations can discover, develop, and
deliver therapies. Its ability to process and synthesize
vast, complex data - across structured clinical records,
scientific literature, omics datasets, manufacturing logs,
and HCP interactions - makes it uniquely suited to
solving some of the industry’s most persistent
bottlenecks. From early discovery to commercialization,
GenAI is enabling new levels of automation, insight
generation, and decision support.
The observed value from early pilots - ranging from
accelerated protocol design and reduced batch
deviations to automated medical content generation -
signals that GenAI is not merely incremental, but
foundational. As the technology matures, it is poised to
become a strategic enabler of faster innovation cycles,
leaner operations, and more personalized healthcare.
Yet the full realization of this potential is far from
guaranteed. Success will require more than technical
experimentation: it will demand integrated data
ecosystems,
fit-for-purpose
governance,
cross-
functional upskilling, and clear change leadership.
Companies must also balance innovation with
compliance by establishing rigorous validation,
monitoring, and auditability frameworks - particularly in
regulated, GxP-critical environments.
Ultimately, GenAI will not replace human expertise in
life sciences - it will augment it. Organizations that invest
now in responsible, scalable adoption will be better
positioned to navigate the growing complexity of
biomedical innovation and deliver improved outcomes
for patients, providers, and stakeholders alike.
References
1.
McKinsey & Company. (2024).
Generative AI in the
pharmaceutical industry: Moving from hype to
reality
;
The American Journal of Medical Sciences and Pharmaceutical Research
21
https://www.theamericanjournals.com/index.php/tajmspr
The American Journal of Medical Sciences and Pharmaceutical Research
pharmaceutical-industry-moving-from-hype-to-
reality
2.
U.S. Food & Drug Administration. (2024).
Using
Artificial Intelligence & Machine Learning in the
Development of Drug and Biological Products
;
https://www.fda.gov/media/167973/download
3.
McKinsey & Company. (2023).
Simplification for
success: Rewiring the biopharma operating model
;
4.
Zheng, Y., Koh, H. Y., Yang, M., Li, L., May, L. T.,
Webb, G.
I., Pan, S., & Church, G. (2024).
Large
language
models
in
drug
discovery
and
development: From disease mechanisms to clinical
trials
.
arXiv
https://arxiv.org/abs/2409.04481
5.
McKinsey & Company. (2024).
Faster, smarter trials:
Modernizing biopharma’s R&D IT applications
;
6.
Nature Reviews Drug Discovery. (2023).
Generative
AI and the Future of Early Drug Discovery
;
https://www.nature.com/articles/s41573-023-
00388-w
7.
McKinsey & Company. (2024).
Generative AI in
healthcare: Current trends and future outlook
;
8.
European Medicines Agency. (2024).
Reflection
Paper on the Use of Artificial Intelligence in the
Medicinal
Product
Lifecycle
;
9.
MIT Technology Review. (2024).
AI hallucinations
are poisoning medical science
-
how can we fix it
;
https://www.technologyreview.com
10.
Insilico Medicine. (2024).
AI-powered drug discovery
platform
Chemistry42
;
https://insilico.com/chemistry42
11.
Pfizer. (2023).
Innovation Through GenAI in Clinical
Development
12.
Novartis. (2024).
Reimagining Manufacturing with
AI-Driven Digital Twins
13.
AstraZeneca. (2023).
AI in Medical Affairs: Driving
Real-Time
HCP
Engagement
;
14.
Novo Nordisk. (2023).
Omnichannel Engagement
with
GenAI
in
Diabetes
;
